Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses.

Abstract

BACKGROUND:

There is limited information about the long-term outcomes and patterns of progression in patients who have unresectable, liver-confined hepatocellular carcinoma (HCC) with complete response (CR) to transarterial embolization and do not undergo resection or transplantation (LT).

METHODS:

A retrospective review analyzed participants in a randomized trial comparing hepatic artery embolization (HAE) and drug-eluting bead transarterial chemoembolization (DEB-TACE) with doxorubicin who had CR according to modified response evaluation criteria in solid tumors (mRECIST). The overall survival (OS), incidence and patterns of progression, and factors associated with progression were assessed.

RESULTS:

Of the 101 patients in the trial, 37 with CR were included in this study. This cohort had 17 patients treated with HAE (46 %), and 20 patients managed with DEB-TACE (54 %). The median age was 67 years (range, 42-82 years). Most of the cohort were male (86.5 %) and Caucasian (78 %). The median pre-treatment Model for End-Stage Liver Disease (MELD) score was 10, and 70 % of the cohort had Barcelona Clinic Liver Cancer (BCLC) stage B or C. The median follow-up period was 49 months (95 % confidence interval [CI], 9-108 months), and the median OS was 25 months (95 % CI, 18.9-30.9 months). The 3- and 5-year survival rates were respectively 31 % (95 % CI, 16.7-45.9 %) and 18 % (95 % CI, 6.8-32.1 %). The 1- and 2-year cumulative incidences of progression were respectively 76 % (95 % CI, 57.7-86.8 %) and 92 % (95 % CI, 74.5-97.6 %). The most common first site of progression was the previously treated hepatic site or local site (32 %, 12/37). The 3-year cumulative incidence of progression was 65 % (95 % CI, 46.4-78.4 %) for the local site.

CONCLUSION:

Patients with advanced-stage HCC and CR to embolization do not have durable responses and experience inevitable disease progression. Most patients with progression have liver-confined disease and should be evaluated for additional consolidative treatments.

• Authors: Crisanta H Ilagan, Debra A Goldman, Mithat Gönen, Victoria G Aveson, Michelle Babicky, Vinod P Balachandran, Jeffrey A Drebin, William R Jarnagin, Alice C Wei, T Peter Kingham, Ghassan K Abou-Alfa, Karen T Brown, Michael I D'Angelica
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 29 Issue 11 Pg. 6815-6826 (Oct 2022) ISSN: 1534-4681 [Electronic] United States
• PMID: 35838903 (Publication Type: Journal Article)
• Copyright: © 2022. Society of Surgical Oncology.

Chemical References

• Doxorubicin

Topics

• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Hepatocellular (pathology)
• Chemoembolization, Therapeutic
• Doxorubicin
• End Stage Liver Disease
• Female
• Humans
• Liver Neoplasms (pathology)
• Male
• Middle Aged
• Prognosis
• Randomized Controlled Trials as Topic
• Retrospective Studies
• Severity of Illness Index
• Treatment Outcome